It’s long been recognized that some of the groups most likely to get dementia, including African Americans and Hispanics, are greatly underrepresented in clinical trials. Now a new USC study shows that people from certain racial and ethnic groups may be ineligible for Alzheimer’s disease clinical trials because they have lower levels of amyloid protein at early stages of the disease. The study also suggests that Alzheimer’s may progress differently in different populations.
Study links lack of diversity in Alzheimer’s disease clinical trials to differences in amyloid levels
Tech News
-
Free Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
Smart buildings: What happens to our free will when tech makes choices for us?
-
Screenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
Darknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
Privacy violations undermine the trustworthiness of the Tim Hortons brand
-
Why Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars